Roivant Sciences Ltd.
ROIV
$28.98
$1.134.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -265.89M | -113.52M | -223.36M | -206.48M | 169.38M |
| Total Depreciation and Amortization | 691.00K | 921.00K | 1.10M | 8.16M | 1.94M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.34M | -80.14M | 55.04M | -8.74M | -325.47M |
| Change in Net Operating Assets | 9.37M | 7.08M | -37.17M | 34.48M | -53.11M |
| Cash from Operations | -196.48M | -185.66M | -204.38M | -172.57M | -207.25M |
| Capital Expenditure | 4.94M | -7.85M | -4.04M | -811.00K | -1.83M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 74.93M | 154.44M |
| Other Investing Activities | 104.54M | 128.27M | -1.08B | 1.00B | 301.46M |
| Cash from Investing | 109.47M | 120.42M | -1.09B | 1.07B | 454.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -49.09M |
| Issuance of Common Stock | 119.20M | 69.07M | 30.06M | 12.97M | 28.12M |
| Repurchase of Common Stock | -23.86M | -6.48M | -217.83M | -302.91M | -251.98M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 232.86M | -- | -- | 112.78M | -- |
| Cash from Financing | 328.19M | 62.59M | -187.77M | -177.15M | -272.95M |
| Foreign Exchange rate Adjustments | 430.00K | 1.21M | 815.00K | -489.00K | -1.07M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 241.61M | -1.45M | -1.48B | 723.99M | -27.20M |